References
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report: MosquirixTM. [Accessed 2018 Nov 5]. http://bit.ly/2paE1uw.
- World Health Organization. Hepatitis B. Key facts; July 2019 [Accessed 2019 Jul 12]. https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b.
- World Health Organization. WHO position paper on hepatitis B vaccines. Weekly epidemiological record No. 40. 2009; 84:405–20. [Accessed Apr 2019]. https://www.who.int/wer/2009/wer8440.pdf?ua=1.
- Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, Owusu R, Shomari M, Leach A, Jongert E, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11(10):741–49. doi:10.1016/S1473-3099(11)70100-1.
- RTSS Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367(24):2284–95. doi:10.1056/NEJMoa1208394.
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of opinion, mosquirix. [Accessed 5 Nov 2018]. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_for_use_outside_EU/2015/07/WC500190452.pdf.
- World Health Organization. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec. 2016;91(4):33–51.
- Valea I, Adjei S, Usuf E, Traore O, Ansong D, Tinto H, Owusu Boateng H, Leach A, Mwinessobaonfou Some A, Buabeng P, et al. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. Hum Vaccin Immunother. 2018;14(6):1489–500. doi:10.1080/21645515.2018.1442996.
- World Health Organization. Immunization, vaccines and biologicals.The immunological basis for immunization series. Module 22: Hepatitis B. [Accessed 2018 Nov 5]. http://apps.who.int/iris/bitstream/handle/10665/77755/9789241504751_eng.pdf?sequence=1.
- Gerlich WH. The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg. Clin Infect Dis. 2007;44(9):1170–72. doi:10.1086/513296.
- Iwarson S, Tabor E, Thomas HC, Goodall A, Waters J, Snoy P, Shih JW, Gerety RJ. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol. 1985;16(1):89–96. doi:10.1002/(ISSN)1096-9071.
- Waters JA, Pignatelli M, Brown D, O’Rourke S, Lever A, Thomas HC. The immune response to hepatitis B virus. Postgrad Med J. 1987;63:51–56.
- Leuridan E, Van Damme P. B and the need for a booster dose. Clin Infect Dis. 2011;53(1):68–75. doi:10.1093/cid/cir270.
- Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 1989;17(2):70–76. doi:10.1007/BF01646879.